Furthermore, we provide evidence for the efficacy of the platform by identifying upregulation of key genes, SYK, and GADD45β, following the treatment of CLL cells with the drug doxorubicin. The gene discussed is SYK; the disease is B-cell chronic lymphocytic leukemia.